CAR-T boxed warnings: What comes next?
The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This decision follows an investigation into the new safety signal from postmarketing adverse event reports and clinical trials.
In today’s episode, Fierce Pharma’s Angus Liu talks with regulatory experts Mwango Kashoki, M.D., and Steve Winitsky, M.D., to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line.
Related Insights
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Blog
CAR-T product development: an assessment of FDA’s final guidance for industry
Feb 27, 2024
Blog
CAR-T boxed warnings: regulatory precedents and opportunities
Feb 9, 2024
Article
Three ways to improve your chances that insurers will pay for a new CGT
Feb 18, 2021
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Related Insights
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Blog
CAR-T product development: an assessment of FDA’s final guidance for industry
Feb 27, 2024
Blog
CAR-T boxed warnings: regulatory precedents and opportunities
Feb 9, 2024
Article
Three ways to improve your chances that insurers will pay for a new CGT
Feb 18, 2021
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023